Logistic regression analysis for risk factors related to end-stage liver disease among HIV/HBV co-infection patients
10.3760/cma.j.issn.1671-7368.2011.09.010
- VernacularTitle:人类免疫缺陷病毒并乙型肝炎病毒感染者终末期肝病影响因素分析
- Author:
Rongrong YANG
;
Xien GUI
;
Shicheng GAO
;
Yong XIONG
;
Liping DENG
;
Yuping RONG
- Publication Type:Journal Article
- Keywords:
Human immunodeficiency virus;
Hepatitis B virus;
End-stage liver disease
- From:
Chinese Journal of General Practitioners
2011;10(9):641-644
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand major risk factors associated with end-stage liver disease (ESLD) among patients with human immunedeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.Methods Patients with HIV/HBV co-infection were followed-up and factors related to ESLD were analyzed using logistic regression model to estimate odds ratios (ORs) for them. Results A total of 255 patients with HIV/HBV co-infection were investigated, with an incidence of ESLD of 19. 2% ( 49/255 ). Major risk factors associated with ESLD among patients with HIV/HBV co-infection included count of CD4 below 200 cells/μl at baseline, HIV RNA load decreasing to the lower limit of its detection level within six months after antiretroviral treatment (ART), abnormal of serum activities of transaminase (ALT or AST), longer persistently positive of HIV RNA and HBV DNA, and use of lamivudine-based ART, with OR of 6. 503,14. 456, 0. 049, 1. 814, 1. 536 and 0. 012, respectively. Conclusions Lower CD4 count, abnormal serum transaminases, persistent replication of HIV and HBV all are closely related to ESLD in patients with HIV/HBV co-infection. Therefore, lamivudine-based ART should be of choice for patients with HIV/HBV coinfection to decrease incidence of ESLD.
